revised, August 2011.  

The info presented here is for educational purposes only — not to substitute for a

veterinary consultation. Please, seek advice from a professional practitioner before

administering THE drugs LISTED IN THIS ARTICLE.

Various studies suggest that up to 80% of the healthy rabbit population carries the protozoa Encephalitozoon cuniculi in its body, without ever showing clinical symptoms of the disease and without development of the disease. Not much is known about the biology and the life cycle of E. cuniculi and its mode of transmission is not yet fully determined. The main path of transmission seems to be vertical: from mother to her litter, rather than horizontal: via infected droppings and urine. Possibly a rabbit may also be contaminated later in life from an infected companion or from contaminated dirt, although there are numerous examples where an E. cuniculi positive rabbit lived together with an E. cuniculi negative rabbit, without infecting the latter. The presence of the Microsporidae parasites in mammals leads to a micronutrient/vitamin deficiency, which can result in anemia. Not specific information is available for E. cuniculi.

The protozoal parasite attacks the nervous system and major organs, causing a variety of clinical signs that include torticollis (commonly called head tilt or wry neck), liver failure, kidney failure and calcification, incontinence, phacoclastic uveitis, cataracts, fore- or hindquarter paresis (one, or both sides), nystagmus (eye twitching), and/or other neurological symptoms. Invariably the rabbit will die of meningo-encephalitis.

The different treatment options will attempt to kill the E. cuniculi protozoa, but are unable to affect the spores. Dying protozoa will lead to inflammation of the surrounding tissues. To reduce the inflammatory reaction, corticosteroids can be given during 3 days, concurrently with fenbendazole. Since their use is controversial in rabbits, and is best avoided, they can be replaced by NSAISs analgesics, e.g., meloxicam (metacam).

Commonly given treatment: Benzimidazoles

E. cuniculi is now routinely treated with benzimidazoles. While these drugs have successfully treated many rabbits, they may cause mild to moderate elevation of liver enzymes. It is therefore recommended to do a blood test and analysis of biochemical parameters 14 days after starting the treatment.

The action of benzimidazoles is slow, and depends rather on their presence in the gastro-intestinal tract and the blood than on the concentration present. Benzimidazoles will bind to the tubulin of the parasite and block it. The assemblage of this dimeric tubulin protein form microtubules, that plays important functional and structural roles in the parasites (transport of nutritive molecules, cell division). Benzimidazoles will furthermore block a certain metabolism of parasites, such as the transport and uptake of glucose, without affecting the host (rabbit, cat, dog). The properties of the various benzimidazoles used in the treatment of E. cuniculi varies:

Albendazole is known to be broken down in the liver into more hydrophilic products, which decreases its capacity to pass though the brain-blood barrier; the efficacy of the breakdown products against E. cuniculi is, however, not known. The use of albendazole, a drug not licensed for use in rabbits, has led to the sudden death of healthy rabbits or the appearance of bone marrow failure, although this has not been clinically tested.

It was generally found that albendazole was less efficacious that oxibendazole.

Oxibendazole is a rather lipophilic molecule that is not degraded in the body. The advantages of oxibendazole are its passage through the blood-brain barrier into the brain or CNS (Central Nervous System), its lack of teratogen properties in rabbits, and its non-degradation in the liver, prior to passing in the body, unlike albendazole. It is, however, no yet know to what extent oxibendazole is efficacious against E. cuniculi, and what are the long-term side effects of this compound.

Fenbendazole was studied for its preventive and curing properties in rabbits affected by E. cuniculi and the results have been reported in a scientific journal (Veterinary Record, 2001, pp.478-480). This was a major breakthrough, both because there was scientific data to support the findings and because this was the first treatment that was believed to cure (rather than simply control) the condition. It was furthermore shown that fenbendazole alone crosses the blood-brain barrier in mice. In rare cases, long-term intake of fenbendazole has been associated with the onset of bone marrow failure, digestive problems and anorexia, though this was not clinically investigated. After discussion with vets who treated hundreds of rabbits with fenbendazole, none observed the onset of bone marrow failure in the treated rabbits, given the correct doses during 28 days.

REMARK:

Fenbendazole remains currently the drug of choice for the treatment of E. cuniculi.

Lab rabbits have shown a high titer one year after being treated with fenbendazole and upon autopsy, the presence of the parasite was observed in their brain. These rabbits were however, clinically asymptomatic.

Lately however, more and more rabbits treated with one or with several benzimidazoles compounds showed relapse during the treatment period or after the treatment was stopped. Recently, several caretakers who have been treating rabbits long-term with oxibendazole have reported that the treatment gradually stops working, as if the parasite is developing a resistance to it. Or could two different parasites infect the rabbit, like E. cuniculi and toxoplasmosis ?

Use of pyrimethamine ?

Based on scientific literature or a veterinary’s experience, some alternative drugs are tried in “desperate cases”, rabbits that faced euthanasia. The tried compounds include lufenuron, pyrimethamine (used to treat toxoplasmosis in rabbits) or ponazuril combined with fenbendazole (5 days and 28 days, respectively) and have shown more or less successful.

A treatment protocol for E. cuniculi was developed based on treatment against Sarcocystis sp. or Toxoplasma sp. in horses and cats, respectively, using the anti-protozoal drug pyrimethamine (Daraprim), associated with trimethoprim-sulfa coupled with non-steroidal anti-inflammatory. The treatment is given during one month in horses and two weeks in cats. Side effects appear to be rare.

Although a previous study showed that pyrimethamine was ineffective against E. cuniculi at the studied concentrations of 5 and 20 mg/ml, the 50 mg/ml showed a 35% growth inhibition. Recent preliminary in-vivo tests have, however, shown that the growth of E. cuniculi spores was stopped in presence of therapeutic concentration of pyrimethamine (1 mg/kg).

In rabbits, pyrimethamine has been used to treat toxoplasmosis, Pneumocystis carinii, hepatic coccidial infection, etc. It has been shown that use of pyrimethamine is safe in rabbits when used at the right dosage. The anti-protozoal drug will directly attack the parasite, where it will both block the metabolism of folic acid in the parasite and increase the activity of trimethoprim-sulfa against the parasite.

This treatment is based on a protocol used in cats, for the treatment of toxoplasmosis.